[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100512140":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":28,"locations":11,"responsibleParty":34,"collaborators":36,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":11,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":11,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":11,"overallStatus":71,"whyStopped":11,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":11},{"fullName":5,"class":6},"Global Coalition for Adaptive Research","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention B Vilazodone","EXPERIMENTAL",null,[13],"Drug: Intervention B Vilazodone Hydrochloride (HCl)",{"label":15,"type":16,"description":11,"interventionNames":17},"Intervention B Placebo","PLACEBO_COMPARATOR",[18],"Drug: Intervention B Placebo",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Intervention B Vilazodone Hydrochloride (HCl)","Vilazodone HCl will be administered at 10 mg once daily for 7 days, followed by 20 mg for 7 days, followed by 40 mg for the remainder of the trial. There must be a minimum of 7 days between dosage increases. One reduction in dose due to tolerability will be allowed. After Week 8, dose reduction for tolerability is allowed, but dose increase is not allowed.",[9],{"type":21,"name":15,"description":26,"armGroupLabels":27,"otherNames":11},"A matching placebo will be administered at 10 to 40 mg daily in the same regimen as the intervention.",[15],[29],{"name":30,"role":31,"phone":32,"phoneExt":11,"email":33},"Please visit the website:","CONTACT","ptsdclinicaltrial.org","info@gcaresearch.org",{"type":35,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[37,40,43,45,47,49],{"name":38,"class":39},"U.S. Army Medical Research and Development Command","FED",{"name":41,"class":42},"PPD Development, LP","INDUSTRY",{"name":44,"class":6},"Berry Consultants",{"name":46,"class":42},"Idorsia Pharmaceuticals Ltd.",{"name":48,"class":42},"Cambridge Cognition Ltd",{"name":50,"class":42},"Citeline","100512140","phase-2-department-of-defense-ptsd-adaptive-platform-trial---intervention-b---vilazodone-100512140",false,"NCT05948579","Department of Defense PTSD Adaptive Platform Trial - Intervention B - Vilazodone","A Phase 2, Multi-center, Multi-arm, Randomized, Placebo-controlled, Double-blind, Adaptive Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Potential Pharmacotherapeutic Interventions in Active-Duty Service Members, Veterans, and Non-Veteran Civilians With PTSD","Inclusion Criteria:\n\nNo additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT05422612).\n\nExclusion Criteria:\n\nThe following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol (NCT05422612).\n\n1\\. History of treatment for PTSD with vilazodone at doses of 20 to 40 mg daily, for at least 4 weeks.",true,"ALL","18 Years","65 Years",{"count":63,"type":64},200,"ESTIMATED","INTERVENTIONAL",[67],"PHASE2","This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design.\n\nIntervention B - Vilazodone will assess the safety and efficacy of vilzodone in participants with PTSD.\n\nPlease see NCT05422612 for information on the S-21-02 Master Protocol.",[70],"Post Traumatic Stress Disorder","NOT_YET_RECRUITING","2026-05-18",{"date":74,"type":75},"2026-05-20","ACTUAL",{"date":77,"type":64},"2027-08",{"date":79,"type":64},"2028-05",{"name":5,"class":6}]